Compare · GPCR vs NVO
GPCR vs NVO
Side-by-side comparison of Structure Therapeutics Inc. (GPCR) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GPCR and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.15B, about 64.8x GPCR ($2.95B).
- Over the past year, GPCR is up 84.5% and NVO is down 45.0% - GPCR leads by 129.5 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 2 for GPCR).
- NVO has more recent analyst coverage (25 ratings vs 16 for GPCR).
- Company
- Structure Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $41.90+0.96%
- $43.37+1.36%
- Market cap
- $2.95B
- $191.15B
- 1M return
- +10.94%
- -7.79%
- 1Y return
- +84.51%
- -44.96%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2023
- News (4w)
- 2
- 8
- Recent ratings
- 16
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest GPCR
- Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity
- Structure Therapeutics Announces Participation in Upcoming Investor Conferences
- SEC Form 10-Q filed by Structure Therapeutics Inc.
- Structure Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SEC Form 424B5 filed by Structure Therapeutics Inc.
- Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
- Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions
- Canaccord Genuity initiated coverage on Structure Therapeutics with a new price target
- SEC Form DEF 14A filed by Structure Therapeutics Inc.
- COO & GC Lang Matthew was granted 184,614 units of Ordinary Shares (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care